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Abstract  
Glucose-6-phosphate dehydrogenase (G6PD) Deficiency is the most prevalent enzymopathy in mankind. It has sex-linked 
inheritance. This enzyme exists in all cells.  G6PD deficiency increases the sensitivity of red blood cells to oxidative dam-
age. G6PD deficiency was discovered in 1950 when some people suffered hemolytic anemia as a result of taking antimalar-
ial drugs (primaquin). Most people with G6PD deficiency do not have any symptoms, till they are exposed to certain medi-
cations, Fava beans and infections; and then their red blood cells are hemolyzed. The degree of hemolysis changes accord-
ing to the degree of enzyme deficiency and the oxidant agent exposure. G6PD deficiency has many different variants and 
Mediterranean variant is the most common mutation in the world. G6PD deficiency is considered a health problem world-
wide, especially in Asia, Middle East and Mediterranean countries. In this article, we have reviewed the importance and 
function of G6PD enzyme, incidence rate of G6PD deficiency in the world and Iran, genetic and variants of this enzyme, 
clinical manifestation, diagnosis and treatment of the enzyme deficiency. 
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Introduction 
Glucose-6-phosphatase dehydrogenase (G-6-PD) 
deficiency is the most common enzymopathy in 
humans (1). G6PD deficiency was discovered for 
the first time when hemolytic anemia occurred 
in some persons who consumed anti-malarial drug 
named primaquine (1, 2). It is an X-linked dis-
order and is a highly polymorphic enzyme. This 
enzymopathy affects 400 million people world-
wide (3). The enzyme gene is located on the long 
arm of the X- chromosome (Xq28) (1).  
G6PD catalyzes the first step of pentose phos-
phate pathway, during this reaction NADPH is 
produced and protects red blood cells from 
oxidative damage (4-6). 
Most deficient people do not show any symp-
toms until following exposure to oxidative drugs, 
some infections and ingestion of Fava bean (1). 
Mediterranean mutation is the most common vari-
ant of enzyme deficiency and often associated 
with favism (2, 3).  
Avoiding of the oxidative agents that induces he-
molytic anemia is the most important treatment 
in the enzyme deficiency. Neonatal screening and 
health education can reduce the incidence rate 
of G6PD deficiency clinical manifestations (1).  
The goal of this article is to review the importance 
of G6PD enzyme in antioxidant defense enzyme 
system, function of the enzyme, prevalence of 
G6PD deficiency in the worldwide, structure and 
different mutations of this enzyme, The major cli-
nical manifestations like acute hemolytic anemia 
induced by oxidative drugs and some infections, 
neonatal jaundice and chronic non-spherocytic he-
molytic anemia, diagnosis and treatment of the en-
zyme deficiency. 
Importance of G6PD Enzyme 
Super oxide, hydrogen peroxide, hydroxyl radical 
is called ROS (Reactive Oxygen Species). They 
cause oxidative stress and damage cell’s Mem-
branes (7, 8).  
Increased production of ROS or decreased anti-
oxidant defense enzymes play a major role in oxi-
dative injuries in different organs, tissues and cells 
including brain, heart, vascular cells (8) and ca-
uses brain diseases like Alzheimer and Parkin-
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son diseases and also considered to contribute 
to the aging process (9-11). 
Enzymes like superoxide dismutases, catalase, glu-
tathione peroxidases, glutathione reductase and 
glucose-6-phosphate dehydrogenase are antioxi-
dant defense enzymes. In body defense anti-oxi-
dant system, G6PD is considered as an essential 
modulator enzyme that has a very important role 
in all cells especially in red blood cells (8).  
To know the crucial role of G6PD, at first the 
role of other anti-oxidant enzymes must be un-
derstood. Superoxide dismutase converts two su-
per oxide radicals into one hydrogen peroxide 
and one oxygen (8). Catalase converts hydrogen 
peroxide into water and oxygen (8, 12). Gluta-
thione peroxidase is necessary for reducing hy-
drogen peroxide and lipid peroxides to water 
and lipid alcohols (8). Glutathione reductase: main 
role of this enzyme is regenerating reduced glu-
tathione (GSH) from oxidized form (GSSG) (8, 12). 
G6PD is a key enzyme for maintenance of re-
dox potential in cells. G6PD produces NADPH in 
pentose phosphate pathway. NADPH is impor-
tant as a central reductant and regulates of re-
dox potential (13). It also acts as a cofactor for 
other anti-oxidant enzymes like glutathione reduc-
tase (8, 12). 
Reduced glutathione is required as a cofactor for 
the glutathione peroxidases and, thus reduced glu-
tathione and glutathione cycles is crucial for neu-
tralization of hydrogen peroxide and lipid per-
oxides and also protects protein sulfhydryl groups 
against oxidation (2).  
Catalase is found in two forms, active and inac-
tive, NADPH is critical for conversion of inac-
tive form into active form (2). 
Different studies point out the importance of 
G6PD enzyme in other cell functions like its con-
trol of cell death. G6PD is a principal enzyme in 
cell death and intracellular redox potential needs 
to be regulated to control cell death (13). As the 
production of ROS increases, so does cell death.  
In another study, role of anti-oxidant enzyme and 
oxidative stress in Parkinson disease was sur-
veyed. One hundred and fifteen patients with 
Parkinson and 37 healthy people were selected. 
In these samples, activities of superoxide dismuta-
se, Catalase, Glutathione peroxidase and G6PD 
in red blood cells were measured. They showed 
that activities of this enzyme in patients were sig-
nificantly lower than normal person. These find-
ings demonstrated that oxidative stress is the main 
cause of the start and progress of neurodegen-
erative in the patients and can also be related 
with intensity of the disease (14). 
Function of G6PD 
G6PD catalyzes the first step in the pentose phos-
phate pathway, converts Glucose-6-phosphate into 
6-phosphogluconolactone and during this conver-
sion, the important reductant metabolite named 
NADPH is provided. The pathway is the only 
source for producing of NADPH in red blood 
cells (2), because they lack mithochondria, nu-
cleus and ribosomes and other pathways that 
produce NADPH(4). NADPH is necessary for 
generating of GSH from its oxidized form, GSSG, 
and subsequent maintenance of intracellular GSH 
pools. GSH maintains normal structure, elastic-
ity and integrity of red blood cells, and sustain 
hemoglobin in ferrous state that is essential for 
carrying oxygen (4). G6PD and NADPH are key 
factors for protection of red blood cells from 
oxidative damage and peroxides (2). Peroxides 
are usually removed from red blood cells by 
glutathione peroxidase that uses reduced glu-
tathione. Reduced glutathione reacts with harm-
ful peroxides and neutralize them. In this reac-
tion reduced glutathione is oxidized and gluta-
thione reductase regenerates reduced glutathione 
by using of NADPH. NADPH is oxidized and 
G6PD is required for producing reduced NADPH 











Fig. 1: Function of G6PD (5) 
 
Catalase is another anti-oxidant enzyme that is 
abundant in red blood cells and helps to the re-
moval of peroxides from red blood cells through 
activation by NADPH (2). Unless peroxides are 
neutralized, they will cause oxidative injuries. He-
moglobin and red blood cell membrane molecules 
that contain SH groups are destroyed (1, 2).  
Hemoglobin is denatured irreversibly, precipitates 
and forms Heinz bodies. Heinz bodies destroy 
membranes of red blood cells then leads to hae-
molysis and acute anemia. 
Regarding to the roles of NADPH in redox state 
of cells, G6PD is the principal enzyme in chain 
reaction that is necessary for protecting all cells 
especially red blood cells against oxidant agents 
(2). Then G6PD-deficient cells especially red 
blood cells are susceptible to damage by reac-
tive oxygen species and oxidative stress (2). 
Malaria and G6PD deficiency 
The geographical distribution of malaria is similar 
to the world distribution of deficient G6PD vari-
ants. It is postulated that the high frequency of 
G6PD deficiency has arisen because G6PD de-
ficient variants confer some resistance against se-
vere malaria caused by Plasmodium falciparum 
(4, 15, 16). The exact mechanism of this protec-
tion is still unknown. Red blood cells are the host 
cells for Plasmodium falciparum. Plasmodium 
parasites oxidize NADPH and diminish the level 
of reduced glutathione (GSH) in red blood cells. 
This effect in G6PD deficiency is more severe, 
leading to oxidative-induced damage to the RBC 
(4). Also Plasmodium parasites break down he-
moglobin, and release toxic substances like Fe, 
which is a source of oxidative stress and it will 
cause hemolysis (17). Therefore the growth of 
Plasmodium parasites is decreased. In addition, 
damaged red blood cells are removed by phago-
cytosis at an early ring-stage of parasites’ matu-
ration, and that decreases the growth of parasites 
even more (1, 18). 
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Farhud et al. performed a study in the north of 
Iran. They measured serum proteins and immu-
noglobulins in favic patients and healthy controls, 
both school boys. The results showed higher 
amounts in healthy individuals and normal range 
in patients. The normal range in the patients is 
suggested to be due to positive selection that in-
duces a developed immune response and pro-
duces better chances not to get affected by some 
other endemic infectious diseases such as ma-
laria (19).  
Genetics, structure  
The gene for the G6PD enzyme is one of the 
important genes located on the telomeric region 
of the long arm of X chromosome (Xq28) (1, 5, 
20), are more likely to affect males than females. 
Males are more likely than females to suffer all X- 
linked genetic conditions, such as G6PD deficiency 
(21). 
Clinical and biochemical analyses  have character-
ized more than 400 (2, 22) variants most emerg-
ing from point mutations in the coding region 
of gene (2, 23), base changes that result in amino 
acid substitution, displaying a field of pheno-
types with different abnormal enzyme activity 
and wide ranging degree of clinical symptoms 
(23). Monomer of G6PD has 515 amino acids 
with a molecular weight 59 kDa (2, 24). 
G6PD in the active form consists of the same sub-
units of either dimmer or tetramer and includes 
tightly bound NADP (2, 24). It is supposed that 
Lys and Arg, amino acids 386 and 387 in en-
zyme, bind one of the phosphates in NADP (2). 
The shift between two active forms depends on 
PH. Aggregation of inactive monomers and con-
version into an active form requires presence of 
NADPH (2, 24).  
Variants of G6PD 
According to the level of enzyme activity, World 
Health Organization classified variants of G6PD 
to five groups (15, 25). 
Class 1: Severe deficiency of the enzyme with 
Chronic nonspherocytic hemolytic anemia. 
Class 2: Severe deficiency of the enzyme, en-
zyme activity is less than 10% of normal.   
Class 3: Moderate deficiency of the enzyme, en-
zyme activity is %10-60 of normal.  
Class 4: Very mild to none deficiency of the en-
zyme, enzyme activity is %60-100 of normal. 
Class 5: There is increased enzyme activity. 
Mutations that are responsible for class 1 variants 
are confined to the NADP binding site of the en-
zyme or glucose-6-phosphate binding site (2, 24). 
They are located near the carboxy end of the en-
zyme (25). They form severe clinical symptoms 
because they are clustered at the position invo-
lved in the dimmer formation of the active form 
of G6PD (26, 27) and influence stability and 
activity of enzyme (27). But mutations that cause 
mild clinical symptoms are located at the amino 
end of the molecule (25). G6PD variants that have 
been discussed in this article are shown in Table 1.  
G6PD variants that have been characterized at 
the DNA level are shown in Table 2. 
 
Table 1: G6PD variants that have been discussed in this article (2) 
 
Biochemical variants Nucleotide substitution Amino acid substitution WHO class 
A-                                         202G           A 
376A           G 
68Val              Met         
126Asn           Asp 
3 
Mediterranean    563C           T 188Ser             Phe 2 
Mahidol    487G           A 163Gly            Ser 3 
Viangchan        871G           A 291Val            Met 2 
Cosenza          1376G         C 459Arg            Pro 2 
Chatham   1003G        A 335Ala    Thr 3 
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Table 2: G6PD variants that have been characterized at the DNA level (2) 
 
Variant Nucleotide Substitution WHO Class Amino Acid Substitution 
Gaohe 95 A             G           2  32 His             Arg 
Gaozhou    
Sunderland 105-107 del           1 35 Ile               del 
Aures 143 T            C           2 48 Ile                Thr 












202 G            A 















68 Val              Met 






241 C           T 
 
          3 81 Arg             Cys 
Lagosanto 242 G           A           3 81 Arg              His 
Vancouver 
 
317 C           G 
544 C           T 
592 C           T 
          1 
 
106 Ser             Cys 
182 Arg             Trp 
198 Arg             Cys 
Sao Borga 337 G           A           4 113 Asp Asn 
A 376 A           G           4 126 Asn            Asp 
Chinese- 4 392 G           T           ? 131 Gly             Val 
Ilesha 466 G           A           3 156 Glu              Lys 
Mahidol 487 G           A           3 163 Gly             Ser 
Plymouth 488 G           A           1 163 Gly            Asp 
Chinese-3 493 A           G           2 165  Asn           Asp 
Shinshu 527 A           G           1 176  Asp          Gly 
Santamaria 542 A           T 
376 A           G 
          2 181   Asp         Val 



























592 C           T 
593  G          C 
          2 
          1 
198 Arg           Cys 
198 Arg           Pro 





637 G          T 
 
 
          1 
 
212 Val            Leu 
 
Harilaou 648 T           G           1 216 Phe            Leu 
Mexico City 680  G          A           3 227 Arg            Gln 
A- 
 
680 G          T 
376 A          G 
          3 
 
227 Arg            Leu 





          1 
 
242-243 
Gly & Thr 
Wayne 
Cleveland 
769 G          C 
820  G         A 
          1 
          1 
257 Arg           Gly 
274 Glu            Lys 
Chinese-1 835 A          T           2 279  Thr            Ser 
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Table 2: Continued… 
 





844 G          C 
 
 
          2 
 




844 G          C 
 
          2 
 
282 Asp           His 
 
Montalbano 854 G          A           3 285 Arg           His 
Viangchan 
Jammu 
871 G          A           2 291 Val           Met 
West Virginia 910 G         T            1 303 Val  Phe 
Kalyam 
Kerala 
949 G        A 
 
           3 
 





968 T        C 
376 A       G 
 
            3 
 
 
323 Leu         Pro 
126 Asn         Asp 
 
Nara 953-976 del             1 319-326 del 
Chatham 1003 G       A             3 335 Ala          Thr 
Fushan 1004 C       A             2 335 Ala           Asp 
Chinese-5 1024 C        T              ? 342 Leu          Phe 
Irepetra 1057 C        T              2 353 Pro           Ser 
Loma Linda 1089 C        A              1 363 Asn          Lys 
Olomouc 1141 T        C              1 381 Phe           Leu 














386 Lys          Glu 
 
 
Guadalajara 1159 C         T              1 387 Arg         Cys 
Mt. Sinai 1159 C         T 
376   A         G 
             1 387 Arg          Cys 





1160 G         A 
 
 
             1 
 
 
387 Arg          His 
 














393 Arg          His 
 
 
Alhambra 1180 G           C               1 394 Val           Leu 
Puetro Limon 1192 G           A               1 398 Glu           Lys 
Riverside 1228 G           T               1 410 Gly           Cys 
Japan 
Shinagava 
1229 G           A 
 
              1 
 
410 Gly           Asp 
 
Alhambra 1180 G           C               1 394 Val           Leu 
Puetro Limon 1192 G           A               1 398 Glu           Lys 
Riverside 1228 G           T               1 410 Gly           Cys 
Japan 
Shinagava 
1229 G           A 
 
              1 
 
410 Gly           Asp 
 
Alhambra 1180 G           C               1 394 Val           Leu 
Puetro Limon 1192 G           A               1 398 Glu           Lys 
Riverside 1228 G           T               1 410 Gly           Cys 
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Table 2: Continued… 
 
Variant Nucleotide Substitution WHO Class Amino Acid Substitution 
Alhambra 1180 G           C               1 394 Val           Leu 
Puetro Limon 1192 G           A               1 398 Glu           Lys 
Riverside 1228 G           T               1 410 Gly           Cys 
Japan 
Shinagava 
1229 G           A 
 
              1 
 
410 Gly           Asp 
 
Tokyo 1246 G          A               1 416 Glu           Lys 
Georgio 1284 C          A               1 428 Tyr           End 
Varnsdorf 3
/ interon 
10 splice site del               1 N/A 
Pawnee 1316 G          C               2 439 Arg          Pro 
Telti 
Kobe 
1318 C          T 
 
              1 
 440 Leu          Phe 
Santiago de Cuba 1339 G          A                1                 447 Gly          Arg 
Cassano 1347 G          C                2 449 Gln           His 
Union 
Maewo 1360 C           T                2 454 Arg           Cys 
Andalus 1361 G           A               1 454 Arg            His 
Cosenza 1376 G           C               2 459 Arg             Pro 
Taiwan-Hakka 
Gifu-like 1376 G          T 
              2 




















Campinas 1463 G         T              1 488 Gly            Val 
 
G6PD deficiency in the World 
Based on the findings of WHO, 7.5% of the world 
populations have one or two genes for G6PD de-
ficiency and 2.9% are G6PD deficient (28).  
The best known G6PD-deficient variants that oc-
cur at a high frequency are G6PD A- and the Me-
diterranean variants. Mediterranean mutations are 
identified by very low activity in red blood cells 
(29). Mediterranean variant is the most com-
mon variant in Southern Europe, Middle East, 
and India (2). Rate of incidence of Mediterra-
nean mutation in Turkey is (77%), Iran (69%), 
India (60.4%), and also in Pakistan (30) and 
Saudi Arabia the Mediterranean mutation is the 
prevalent variant (31).  
In Kuwaiti population, the most common variants 
are G6PD A- and the Mediterranean variants and 
also a lower rate of Chatham variant and Aures 
are detected in Kuwaiti population. Postulating 
that gene flow from the Indian Sub-continent, 
sub-Saharan Africa and other parts of Mediter-
ranean is responsible for molecular heterogenity 
of G6PD variants in the population (30, 32). The 
most G6PD variant in Italy, Sardinia and Greece 
is G6PD Mediterranean. 
In Egypt and Libya, North of Africa, G6PD Me-
diterranean is the most common variant (30). 
G6PD A- and G6PD Mediterranean have re-
spectively the highest rate of incidence in Alge-
ria and both of them are associated with Fav-
ism. Molecular heterogenous G6PD deficiency 
in Algeria suggests gene flow from Sub-Saharan 
Africa and other parts of Mediterranean (33). 
G6PD A- is found in Africa, Southern Europe and 
all areas African people were taken to (2). G6PD 
deficiency in Spain is heterogenous. The most 
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prevalent variant in Spain is G6PD A-. Two other 
important variants are Seattle and Union. The ex-
istence of G6PD Aures and Santamaria, that are 
polymorphic in Algeria, suggests significant gene 
migration from Africa to Europe through Spain 
(30, 34). 
G6PD deficiency in Mexico is heterogenous and 
G6PD A- is relatively prevalent. Prevalence of 
G6PD A- and Seattle mutations in Mexico were 
likely introduced by African slaves and Spanish 
immigrants (35). 
Viangchan, Mediterranean and Mahidol are com-
mon G6PD mutations in the Malays (36). Vi-
angchan, Mahidol and canton were the most pre-
valent G6PD variants in Thais. G6PD Viangchan 
in Laotians and non-Chinese Southeast Asian po-
pulation is probably the most common variant (37). 
G6PD deficiency in IRAN 
The prevalence of G6PD deficiency in Iranian po-
pulation is 10-14.9% reported by WHO (28). 
The most prevalent variant of G6PD deficiency in 
Iran is the Mediterranean (38-40), and the next 
most prevalent variant is Chatham, and Chat-
ham incidence rate is 13-27% (39).  
The incidence rates of G6PD mutations in dif-
ferent provinces in Iran are shown in Table 3.
 
Table 3: The Prevalence of G6PD mutations in provinces of Iran (38, 40) 
 
 Khorasan Mazandaran Golestan Hormozgan Sistan and 
Balochestan 
Gilan kermanshah 
Percent of Medit 
mutation 




12 27 26.8 8.21 2.17 9.7 7.3 
 
The incidence rate of G6PD deficiency in Tehran 
neonates was 2.1% (41). In a study in Kerman-
shah Province 5.3% of samples were severely 
deficient in G6PD enzyme. Polymorphic muta-
tions in the region were Mediterranean, Chat-
ham, Cosenza (40). There are higher prevalence 
of G6PD deficiency in northern and southeast-
ern provinces of Iran (8.6- 16.4% in Northern 
provinces, 12% in southern part [Shiraz] and 
19.3% in southeastern of Iran) (42, 43-45). 
The three mutations found in the three northern 
provinces of Iran were Mediterranean, Chatham, 
Cosenza (42). Khalili et al reported the preva-
lence of G6PD deficiency in Gilan, a northern 
province of Iran 6.4% (46). In Khorasan, North-
eastern province of Iran, 22% of samples did not 
display one of the known mutations in Iran. Dif-
ferent ethnic groups who are living in this prov-
ince include Persian, Turkmen, Afghan, Turk, Kurd 
and Arab. The unknown variants of enzyme de-
ficiency observed in the region may bear simi-
larities to those in Khorasan neighboring such 
as Afghanistan and Turkmenistan (30).  
Clinical Manifestations of G6PD deficiency 
Acute hemolytic anemia, neonatal jaundice and 
chronic non spherocytic hemolytic anemia are the 
major clinical manifestations associated with G6PD 
deficiency that discussed in this article: 
 
1. Acute hemolytic anemia 
      a. induced by oxidative drugs 
      b. Favism 
      c. Infection-induced hemolysis 
2. Chronic non spherocytic hemolytic anemia 
3. Neonatal jaundice 
 
1. Acute hemolytic anemia 
Unless exposed to oxidative agents like oxidative 
drugs, infections and ingestion of fava beans, 
most patients with G6PD deficiency show no 
sign of acute hemolytic anemia (1, 4). Hemolytic 
anemia in G6PD A- is self-limited because in this 
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mutation the younger red blood cells contain 
normal G6PD enzyme activity. But in Mediter-
ranean G6PD with severe enzyme deficiency, he-
molytic anemia is not self-limited. All red blood 
cells have enzyme deficiency and don’t resist in 
hemolysis (2, 15, 47).  
a. Induced by oxidative drugs 
Each person’s response to specific drugs is af-
fected by genetic variations in an enzyme or en-
zyme system (48). Adverse drug reactions (ADRs) 
are a significant cause of morbidity and mortal-
ity. Acute hemolytic anemia induced by anti-ma-
larial drugs is an example of adverse drug reac-
tions that had been recognized for long time in 
G6PD deficient people. In these people, due to 
a defect in the gene coding for G6PD, the activ-
ity of the enzyme is reduced and that caused 
this adverse effect (49). Pharmacogenetics was in-
troduced by Vogel in 1959 for study the re-
lationship between genetic variations in genes in-
volved in drug metabolism and drug response. 
More recently, the term pharmacogenomics has 
also been introduced, that is the broader appli-
cation of genomic technologies and considers the 
genetic variants, patterns of gene expression and 
the way drugs influence gene function. It is pos-
tulated that pharmacogenomics is the study of 
entire genome, meanwhile pharmacogenetics is 
the study of a single gene. The term pharma-
cogenomics can be used to cover both Pharma-
cogenetics and Pharmacogenomics. Pharmacoge-
nomics offers major potential benefits by im-
proving drug response, reducing ADRs and un-
derstanding disease susceptibility (50). 
Some drugs cause oxidative stress and induce he-
molysis in G6PD-deficient red blood cells. They 
form hydrogen peroxide when they come in con-
tact with hemoglobin (47). 
During this reaction reduced glutathione is oxi-
dized rapidly, glutathione pools are exhausted, 
hemoglobin is denatured and Heinz bodies are 
formed (2, 47). Red blood cells with enzyme de-
ficiency are not capable of reducing NADP to 
NADPH for regenerating reduced glutathione from 
oxidized form that is necessary for inactivating 
peroxides and protecting cells against oxidative 
injuries that cause hemolysis (47, 51). Drugs, 
substances and herbs can induce hemolytic ane-
mia in G6PD deficient people are shown in tables 
4, 5. 
Primaquine 
People with G6PD deficiency are about 20 to 30 
times more sensitive to the hemolytic activity of pri-
maquine than the people with normal G6PD (52). 
Mechanism for induction of hemolytic anemia 
was studied in rats (52, 53). Toxic metabolites of 
primaquin cause reduction of GSH in red blood 
cells (53), formation of methemoglobin (51) and 
Heinz bodies that induce hemolytic anemia (52, 
53). The primaquine metabolite, 6-methoxy-8-hy-
droxylaminoquinoline after N-hydroxylation from 
6-methoxy-8-aminoquinoline (52), by peroxida-
tion of lipids in red blood cells with significant 
GSH and oxidation of protein in GSH-depleted 
red blood cells can induce hemolytic response 
(52). 
Henna 
Henna is a cosmetic dye that is used for dying 
hair, nails (54, 55) and also for treatment der-
matitis (56). Some studies identified that henna 
can induce hemolytic anemia (55, 57, 58). Law-
sone (2-hydroxy-1,4-naphthoquinone) is a che-
mical substance in henna, and its structure and re-
dox potential is similar to naphthalene metabolites 
that induce oxidative damage in red blood cells 
especially in G6PD-deficient person (55). 
Tea and Polyphenols 
In a study in China effects of extracts of black 
tea, green tea and decaffeinated green tea and 
their polyphenols on G6PD-deficient red blood 
cell in vitro were examined. The results showed 
that extracts of tea and their two polyphenol (epi-
gallocatechin-3-gallate and epigallocatechin) cha-
nged oxidative condition in G6PD- deficient red 
blood cells in vitro. Level of GSH is lowered; me-
themoglobin, hemoglobin and GSSG are raised. 
The observed changes depend to doses of tea ex-
tracts and polyphenols that are used. These cha-
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Table 4: Drugs and substances should be avoided by G6PD deficient individuals (1, 2, 60). 
 
Drugs and substances (group) Examples 
Anti malarial drugs   Primaquin 
Sulphonamides    Sulphacetamid, Sulphametoxazole, Sulphanilamid, Sulphapyridin                                  
Sulphones                                    Thiazolesulfone, Dapsone 
Other sulphur-containing drugs Glibenclamide           
Nitrofurans Nitrofurantoin(Furadantin)         
 Other drugs Toluidin blue, Trinitrotoluene(TNT), Urate oxidase, Phenylhydrazine, Furazolidone (Furoxone), 
Methylene Blue, Nalidixic acid, Niridazole, Phenazopyridine, Isobutyl Nitrite,  Acetanilide,  Aspirin    
Cosmetic substance                     Henna 
Other substances                         Naphthalene, Moth balls, High-dose of  vitamin K or ascorbic acid 
Food substance    Fava beans 
 
Table 5: Drugs and Substances (with their molecular formulation) should be avoided by G6PD deficient individuals 
according to the G6PD Deficiency Association (61) 
 
Name Molecular Forumla Risk Levels      Population at risk 
Acetanilide (acetanilid)  C8 H9 N O High Medit., Asian 
Acetylphenylhydrazine (2-Phynylacetohydrazide)  C8 H10 N2 O High All 
Aldesulfone sodium (sulfoxone)  C14 H14 N2 Na2 O6 S3 High All 
Aminophenazone (aminopyrine)  C13 H17 N3 O Low All 
Antazoline (antistine)  C17 H19 N3 Low All 
Arsine  As-H3 High All 
Ascorbic Acid  C6 H8 O6 Low All 
Beta-Naphthol (2-Naphthol)  C10 H8 O High All 
Chloramphenicol  C11 H12 C12 N2 O5 High Medit., Asian 
Chloroquine  C18 H26 Cl N3 High Medit., Asian 
Ciprofloxacin  C17 H18 F N3 O3 High Medit., Asian 
Colchicine  C22 H25 N O6 Low All 
Dapsone (diaphenylsulfone)  C12 H12 N2 O2 S High All 
Dimercaprol  C3 H8 O S2 High All 
Diphenhydramine (difenilhydramine)  C17 H21 N O Low All 
Dopamine (L-dopa)  C8 H11 N O2 Low All 
Doxorubicin  C27 H29 N O11 High Medit., Asian 
Furazolidone  C8 H7 N3 O5 High All 
Glibenclamide  C32 H28 Cl N3 O5 S High Medit., Asian 
Glucosulfone (glucosulfone sodium)  C24 H34 N2 Na2 O18 S3  High All 
Isobutyl Nitrite  C4 H9 N O2 High Medit., Asian 
Isoniazid  C6 H7 N3 O Low All 
Menadiol Sodium Sulfate (Vitamin k4 sodium sulfate)   C11 H8 Na2 O8 S2 High All 
Menadione (menaphtone)  C11 H8 O2 High All 
Menadione sodium Bisulfite (Vitamin K3 sodium bisulfite)  C11 H8 O2 NaHSO3 High All 
Mepacrine (Quinacrine)  C23 H3O Cl N3 O High           Medit., Asian 
Mesalazine-5-Aminosalicylic Acid(paraminosalicylic acid) C7 H7 N O3 High Medit., Asian 
Methyltioninium Chloride (methylene blue)  C16 H18 Cl N3 S High All 
Nalidixic Acid  C12 H12 N2 O3 High Medit., Asian 
Naphtalene, Pure (naphtalin)  C10 H8 High All 
Niridazole  C6 H6 N4 O3 S High All 
Nitrofural (nitrofurazone)  C6 H6 N4 O4 High All 
Nitrofurantoin  C8 H6 N4 O5 High All 
Norfloxacin  C16 H18 F N3 O3 Low All 
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Table 5: Continued… 
 
 Name  Molcular Formula Risk Levels           Population at Risk 
O-Acetylsalicylic Acid (acetylsalicylic acid)  C9 H8 O4 High Medit., Asian 
Oxidase, Urate (urate oxidase)  ____________ High Medit., Asian 
Pamaquine  C42 H45 N3 O7 High All 
Para-Aminobenzoic Acid (4-Aminobenzoic Acid)  C7 H7 N O2 Low All 
Paracetamol (acetaminophen)  C8 H9 N O2 Low All 
Pentaquine  C18 H27 N3 O High All 
Phenacetin (acetophenetidin)  C10 H13 N O2 High Medit., Asian 
Phenazone (antipyrine)  C11 H12 N2 O Low All 
Phenazopyridine  C11 H11 N5 High Medit., Asian 
Phenylbutazone  C19 H20 N2 O2 Low All 
Phenytoin  C19 H20 N2 O2 Low All 
Phynylhydrazine  C6 H8 N2 High All 
Phytomenadione (Vitamin K1)  C31 H46 O2 Low All 
Primaquine  C15 H21 N3 O High All 
Probenecid  C13 H19 NO4 S High All 
Procainamide  C13 H21 N3 O  Low All 
Proguanil (chlorguanidine)  C11 H16 Cl N5  Low All 
Pyrimethamine  C12 H13 Cl N4 Low All 
Quinidine  C20 H24 N2 O2  Low All 
Quinine  C20 H24 N2 O2  Low All 
Stibophen (2-(2-Oxido-3,5-Disulphonatophenoxy)-
1,3,2,Benzodioxastibole-4-6-Disulphonate)  
C12 H4 Na5 O16 S4 Sb High 
 
All 
Streptomycin  C21 H39 N7 O12 Low All 
Sulfacetamide  C8 H10 N2 O3 S High All 
Sulfacytine  C12 H14 N4 O3 S Low All 
Sulfadiazine  C10 H10 N4 O2 S Low All 
Sulfadimidine  C12 H14 N4 O2 S High All 
Sulfafurazole (sulfafurazone, sulfisoxazole)  C11 H13 N3 O3 S High Medit., Asian 
Sulfaguanidine  C7 H10 N4 O2 S Low All 
Sulfamerazine  C11 H12 N4 O2 S Low All 
Sulfamethoxazole  C10 H11 N3 O3 S High All 
Sulfanilamide (Sulphanilamide)  C6 H8 N2 O2 S High All 
Sulfapyridine  C11 H11 N3 O2 S High All 
Sulfasalazine, Salazosulfapyridine (salazopyrin)  C18 H14 N4 O5 S High All 
Thiazosulfone (thiazolesulfone)  C9 H9 N3 O2 S2 High Medit., Asian 
Tiaprofenic Acid  C14 H12 O3 S Low All 
Tolonium Chloride, Tolonium Chloride (toluidine 
blue)  
C15 H16 Cl N3 S High All 
Trihexyphynidyl (benzhexol)  C20 H31 N O Low All 
Trimethoprim  C14 H18 N4 O3 Low All 
Trinitrotoluene (2,4,6-Trinitrotoluene)  C7 H5 N3 O6 High Medit., Asian 
Tripelennamine  C16 H21 N3 Low Medit., Asian 
Food substances and herbs that should be avoided by G6PD deficient people 
Fava Beans 
Some prefer also to avoid red wine, all legumes, blueberries (also with yogurt), soya products, tonic water. 
Chinese Herbs to Avoid: Cattle Gallstone Bezoar (Bos Taurus Domesticus), Honeysuckle (Lonicera Japonica), 
Chimonanthus Flower(Chimonanthus Praecox), Huang Lian (黄连), 100% Pearl Powder 
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b. Favism 
Favism is hemolytic anemia which occurs after the 
ingestion of fava beans especially fresh fava beans 
in G6PD-deficient individual and that’s why the 
highest incidence rate of favism is at the time of 
harvest (1, 2, 15, 62).  
Favism is always observed in people with G6PD 
deficiency, but all G6PD-deficient people do not 
develop hemolysis. Therefore, G6PD deficiency 
is an essential factor for the occurrence of favism 
but it is not enough (2, 15). Most cases of favism 
are observed in Mediterranean type of G6PD-
deficient because the level of enzyme activity is very 
low and deficiency is severe, and occasionally in 
individuals with G6PD A- variant (1, 2). 
Clinical symptoms of favism are pallor, jaundice, 
hematuri and acute hemolytic anemia occurs 24-
48 h after consumption of fava beans, suddenly 
(1, 15, 63). Ahaptoglobinemia was found in fav-
ism patients (64, 65). There is a low haptoglo-
bin serum in G6PD deficient individuals. Hap-
toglobin is a serum protein of the alpha-2 frac-
tion, binds to free hemoglobin whenever intravas-
cular hemolysis occurs, the complex cleared by 
phagocytes and then haptoglobin disappeared 
from plasma (65, 66).    
Vicine and convicine are pyrimidine glucoside 
that are abundant in fava beans and make up 6.7 
g/100 g of dry weight of fava beans (67). These 
substances are metabolized by B-glucosidase in 
body to divicine and isoramil that are unstable 
aglycons, and are oxidized rapidly and form hy-
drogen peroxide and superoxide anion. These me-
tabolites oxidize reduced glutathione in normal 
and G6PD-deficient red blood cells (67-69). De-
pletion of reduced glutathione and impairment of 
some important enzyme induce oxidative stress 
in G6PD-deficient red blood cells and lead to 
acute hemolytic anemia called favism (2, 68, 69). 
c. Infection-induced hemolysis 
The most common cause of hemolysis is possi-
bly the infection in G6PD-deficient individuals 
(1, 2). Viral, bacterial and rickettsial infections, 
especially hepatitis, pneumonia and typhoid fever 
induce hemolysis in G6PD- deficient people (1). 
During phagocytosis, leukocytes may release ac-
tive oxygen species that induce oxidative stress to 
the erythrocytes, and will damage them and will 
cause hemolysis (1, 2). 
2. Chronic non spherocytic hemolytic anemia 
Some of the rare variants of G6PD deficiency 
which are designated as class 1 variants, accord-
ing to the classification of WHO, are associated 
with Chronic non spherocytic hemolytic anemia 
(1, 2, 26).  
Individuals in this class have very low enzyme ac-
tivity (26) and suffer from hemolytic anemia even 
when oxidative agents are not present (2). They 
are variably anemic in steady state condition (1, 2). 
Splenomegaly is commonly present. The disorder 
is usually identified during infancy and childhood 
(15). 
3. Neonatal jaundice 
Serum bilirubin levels are determined by produ-
ction of bilirubin, bilirubin conjugation and elimi-
nation. Hyperbilirubinemia is caused by the im-
balance between the rate of production of bilir-
ubin, the end product of heme metabolism, and 
restricted excretion of bilirubin in newborns (70, 
71). The average total serum bilirubin level is 
usually 5-6 mg per dl (86-103 µmol per l) in 
full term newborns (71). Hyperbilirubinemia oc-
curs due to either physiologic or pathologic causes 
(71). Physiologic jaundice occurs when the se-
rum total bilirubin is in a range of 7 to 17 mg 
per dl (104-291 µmol per l). A total serum bilir-
ubin level higher than 17 mg per dL is consid-
ered pathologic hyperbilirubinemia. One of the 
common risk factors for pathologic hyperbilirubi-
nemia in newborn infants is deficiency of G6PD 
enzyme (71). Deficiency of this enzyme is the 
most prevalent enzymopathy in red blood cells 
that causes hemolysis and hyperbilirubinemia (72).  
Hyperbilirubinemia can be very severe in G6PD-
deficiency and induces permanent damage to the 
brain and causes kernicterus and death (72). Over-
production of unconjugated bilirubin and lack of 
proper management of hyperbilirubinemia cause 
changes in the mitochondria of the basal ganglia 
and leads to impaired mitochondrial respiration, 
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The pathogenesis of hyperbilirubinemia in G6PD-
deficient newborn babies is different from that in 
G6PD-normal ones. Meanwhile hemolysis is con-
sidered to be a principal cause of bilirubinemia 
in G6PD-normal neonates; but diminished bilir-
ubin conjugation would be the main cause of hy-
perbilirubinemia in G6PD-deficient newborn in-
fants (70). Profile of serum bilirubin in newborns 
with G6PD-deficiency showed that the amount of 
total and unconjugated bilirubin is high and con-
jugated bilirubin is low. These levels of different 
forms of bilirubin that are seen in the neonates 
are similar in conditions of partial deficiency of 
the bilirubin conjugating enzyme UDP glucurono-
syltransferase, such as Gilberts syndrome. High 
levels of unconjugated bilirubin in G6PD-deficient 
neonates are the result of an interaction between 
G-6-PD deficiency and variant promoter for the 
gene encoding this enzyme, UDP glucuronosyl-
transferase (74).  
Although there is a natural immaturity of bilir-
ubin conjugationin in neonates, the bilirubin con-
jugation ability of G6PD-deficient neonates who 
are also heperbilirubinemic is even less efficient. 
Bilirubin conjugation ability in G6PD-deficient neo- 
nates may become worse due to increased hemo-
lysis and more bilirubin production (70, 74).  
Diagnosis 
Beutler fluorescent spot test, dichlorophenol indo-
phenol decolourization and quantitative spectro-
photometric assey are methods used for the di-
agnosis of G6PD deficiency (15, 75). Beutler fluo-
rescent spot test is the most acceptable method 
for screening of G6PD deficiency (76). During 
this method, the rate of NADPH production from 
NADP by G6PD is measured under ultraviolet 
light (15, 66). G6PD non-deficient blood samples 
fluoresce brightly, but deficient samples show 
little or no fluorescence (75-77).   
When individuals are actively hemolyzing, the 
test can show normal results wrongly, because 
sustaining younger erythrocytes show normal en-
zyme activity or near normal. Thus the indivi-
duals should be screened several weeks after a 
hemolytic episode (15, 75).   
By using the Quantitative spectrophotometric me-
thod, activity of G6PD Enzyme was determined 
by measuring the rate of the reduction of NADP to 
NADPH in the presence of G6P and hemolysate 
(15, 76). Another Screening method for G6PD 
deficiency is dichlorophenol-indophenol (DPIP)dye 
decolorization. This method is used for determin-
ing of G6PD in red blood cells. By this method 
hetrozygotes are diagnosed easily and is used 
when a large number of population are screened 
for determination of G6PD deficiency (15). 
Laboratory tests and clinical features in patients 
with G6PD deficiency and hemolysis are: Hemo-
globinuria, Increased indirect bilirubin, Elavated se-
rum lactate dehydrogenase,  
Low serum haptoglobin (up to ahaptoglobinemia), 
Complete blood count (CBC), elevated reticulo-
cyte count, Heinz bodies are presented on pe-
ripheral blood smear, Comb's test (the test in he-
molysis phase is negative) (77, 78). 
Treatment 
The main treatment for G6PD deficiency is avoid-
ance of oxidative agents like infection, fava beans 
and oxidative drugs that induce hemolysis (1, 4). 
Hemolysis may be so severe that it may even re-
quire blood transfusion (2). Screening of new-
borns for early diagnosis of G6PD deficiency and 
proper education can reduce the incidence of cli-
nical symptoms (1). These methods have been 
successfully applied in northern Sardinia and the 
result was that the incidence of Favism has be-
come less and also in Singapore kernicterus in the 
neonates is now very rare. Proper control and early 
treatment in neonatal jaundice are very impor-
tant (1). Phototherapy is used to decrease bilir-
ubin concentration and when the bilirubin levels 
exceeds 20 mg/dl, exchange transfusion is nec-
essary (2). In regions that G6PD deficiency is pre-
valent, there is a grave danger of giving G6PD-
deficient blood to such newborns and this has to 
be prevented (1). Using desferrioxamine could 
make the attacks of Favism less severe.  Use of 
Sn-mesoporphyrin (SnMP) that inhibits heme ox-
ygenase and decreases bilirubin production in 
G6PD-deficient neonates has  decreased  the  need  
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for phototherapy and exchange transfusion (1, 79, 
80). Because of some adverse effects of Sn-
mesoporphyrin, SnMP should only be used for 
neonates who are in a clear danger of developing 
bilirubin-induced neurologic dysfunction or those 
who are taking part in clinical trials (79). In clini-
cal experiments, use of antioxidants like vitamin 
E and selenium have not shown any benefit for 
the treatment of G6PD deficiency (1). 
Conclusion 
G6PD deficiency is one of the most common 
X-link inherited hemolytic disorders reported, af-
fecting around 400 million people worldwide. The 
main function of G6PD is to protect the RBC 
against oxidative damage. The most important way 
for prevention and reduction in the incidence rate 
of clinical symptoms of G6PD deficiency is to 
avoid oxidative agents like infection, fava beans 
and oxidative drugs that induce hemolysis, also 
screening of newborns for early diagnosis of 
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